Timber Creek Capital Management LLC Boosts Holdings in Becton, Dickinson and Company $BDX

Timber Creek Capital Management LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 124.1% during the 2nd quarter, Holdings Channel reports. The firm owned 36,109 shares of the medical instruments supplier’s stock after purchasing an additional 19,996 shares during the quarter. Becton, Dickinson and Company comprises 1.6% of Timber Creek Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Timber Creek Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $6,387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. XTX Topco Ltd purchased a new position in Becton, Dickinson and Company during the second quarter worth $2,839,000. Clifford Capital Partners LLC purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $12,801,000. Global Retirement Partners LLC acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $1,087,000. HFR Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 3.3% in the 2nd quarter. HFR Wealth Management LLC now owns 34,359 shares of the medical instruments supplier’s stock valued at $5,918,000 after purchasing an additional 1,083 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.5% during the second quarter. Prudential Financial Inc. now owns 191,264 shares of the medical instruments supplier’s stock worth $32,945,000 after buying an additional 2,765 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday, November 7th. Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reduced their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Stock Down 0.7%

BDX stock opened at $191.32 on Tuesday. The firm’s 50-day moving average is $186.94 and its two-hundred day moving average is $182.60. The company has a market capitalization of $54.84 billion, a price-to-earnings ratio of 34.41, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,249 shares of company stock valued at $231,358. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.